Next-generation AAV gene therapy from joined German forces
The viral vector specialist SIRION Biotech GmbH today announces the signing of a preferred partnership agreement with He…
The viral vector specialist SIRION Biotech GmbH today announces the signing of a preferred partnership agreement with He…
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced…
SIRION Biotech GmbH and Vibalogics GmbH, have signed a strategic partnership agreement designed to meet demand from gene…
AMSBIO bietet ab sofort eine neue Palette an gebrauchsfertigen Adeno-assoziierten Viren (AAV) an. Diese Viren eignen sic…
Funds will advance development of ViGeneron’s next-generation ophthalmic gene therapy pipeline and vector platforms Roun…
AMSBIO has established a comprehensive portfolio of knock-out cell lines and lysates generated with CRISPR/Cas9 technol…
SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced…
SIRION Biotech GmbH und Vibalogics GmbH haben eine strategische Partnerschaft unterzeichnet mit dem Ziel, Gentherapiefir…
With the beginning of a new fiscal year SIRION Biotech GmbH, located at the Innovation and Start-Up Center for Biotechno…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX) announced today that it has granted an exclusive, worldwide license for…